TriangleHEALTH PROFESSIONAL · SOURCE READING
Mixed Gliomas Treatment
Source: Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 28, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Primary CNS Tumors by Tumor Type
Patients with mixed glial tumors, which include oligoastrocytoma (WHO grade II) and anaplastic oligoastrocytoma (WHO grade III), have highly variable prognoses based on their status of the IDH1 and IDH2 genes and 1p/19q chromosomes.[27-29] Therefore, the optimal treatment for these tumors as a group is uncertain. Often, they are treated similarly to astrocytic tumors because a subset of tumors may have outcomes similar to WHO grade III astrocytic or WHO grade IV glioblastoma tumors. Testing for these known, strong prognostic molecular markers should be performed, which may help to guide the assessment of risk and subsequent management.
Treatment options for mixed gliomas include:
Surgery plus radiation therapy with or without chemotherapy.
For more information, see the Astrocytic Tumors Treatment section.
Source links and citations
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice